In this task, we defined biomarker as “gene, protein or biological molecule identified in or associated with patient’s/model’s tumour.” Thus, biomarker entities can be mentioned using their full names (e.g., epidermal growth factor receptor, lnc-RP11–536 K7.3, echinoderm microtubuleassociated protein-like 4), standardized gene or protein symbols (NPM1, KRAS, PTEN) or abbreviation of metabolites (NADPH, D2HG). This evidence concerns the gene KRAS and neoplasm.